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Vaccination of infants with bacillus Calmette–Guérin (BCG) activates both the innate and 
adaptive arms of the immune response. The antimycobacterial effects of these responses 
most likely account for the ability of BCG to protect against childhood forms of tubercu-
losis (TB). There is also evidence for a heterologous protective effect of BCG vaccination 
against TB-unrelated mortality in low birth weight infants. A possible mechanism of action 
of this effect, the induction of trained innate immunity, has been demonstrated when 
cells from BCG-vaccinated adults are restimulated in  vitro with non-related microbial 
stimuli. Our aim was to examine an extensive panel of secreted immune biomarkers to 
characterize the profile of trained innate immunity in infants. Stimulation of whole blood 
for 48 h was performed 4 months after BCG vaccination, or in control unvaccinated 
infants. Stimulants were lipopolysaccharide; Pam3Cys (P3C); heat-killed Candida albi-
cans, Staphylococcus aureus, Escherichia coli, and a lysate of Mycobacterium tuber-
culosis. Culture supernatants were tested for secreted cytokines and chemokines by 
42-plex bead array and monocytes and natural killer (NK) cells assessed for expression 
of activation markers by flow cytometry. BCG-vaccinated infants displayed increases 
in 11 cytokines and chemokines in response to different non-specific innate immunity 
stimuli: epidermal growth factor (EGF); eotaxin; IL-6; IL-7; IL-8; IL-10; IL-12p40; mono-
cyte chemotactic protein-3; macrophage inflammatory protein-1α; soluble CD40 ligand 
and platelet-derived growth factor (PDGF)-AB/BB. Although each stimulant induced a 
distinct response profile, three analytes, EGF, IL-6, and PDGF-AB/BB, were commonly 
higher after stimulation with Pam3Cys, C. albicans, and S. aureus. Conversely, certain 
cytokines such as interferon gamma-inducible protein-10, IL-2, IL-13, IL-17, GM-CSF, 
and GRO were suppressed in BCG-vaccinated infants, while no increases in TNFα or 
IL-1β production were detected. We did not observe a concomitant, BCG-associated 
change in monocyte surface activation markers in response to non-specific stimuli, but we 
detected a significant increase in CD69 expression on NK cells in response to Pam3Cys. 
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Pam3Cys-induced NK  cell activation correlated with the magnitude of IL-12p40 and 
IL-10 responses to the same stimulant. This study reveals a novel cytokine/chemokine 
biomarker signature of BCG-induced trained innate immunity in infants and the involve-
ment of NK cells in these responses.
Keywords: bacillus calmette–guérin, vaccination, heterologous effects, trained immunity, infants, cytokines, 
chemokines, natural killer
inTrODUcTiOn
Mycobacterium bovis bacillus Calmette–Guérin (BCG) is cur-
rently the only licensed vaccine for tuberculosis (TB). Although 
its protective efficacy against adult pulmonary TB is variable 
(1–3), BCG affords more reliable protection against childhood 
forms of the disease when administered to infants (4). The 
immune mechanisms responsible for this protection are not 
fully understood, although many studies have described BCG-
induced, antigen-specific immune responses that may play a 
part (5–12).
Evidence also exists of a beneficial effect for the BCG vaccine 
against several different diseases and outcomes other than TB, 
including as a therapeutic agent against bladder cancer when 
instilled directly into the bladder (13) and protection against 
all-cause mortality in low birth weight infants (14). These 
effects are heterologous (non-specific) as they do not rely on 
mycobacteria-specific adaptive immune responses. Exactly 
how BCG mediates these effects is not clear, although different 
pathways are probably involved. Non-specific protective effects 
against mortality in low birth weight infants are a result of resist-
ance to pathogenic microorganisms that are responsible for 
death due to neonatal sepsis and respiratory infections (15, 16). 
The immune responses mediating this effect could be either 
heterologous T-cells (i.e., T-cells induced by an epitope from 
one organism but with cross-reactivity to others) or the ability 
of BCG to potentiate the responsiveness of the innate immune 
system to later infections: a biological process termed trained 
innate immunity which represents a de facto innate immune 
memory (17–19). Such a phenomenon is thought to have existed 
for millions of years as acquired systemic resistance in plants and 
also in invertebrates, neither of which have adaptive immune 
systems (17). Several studies have revealed enhancements of the 
neonatal innate immune response to Gram-positive and Gram-
negative infections following previous encounters, mediated by 
different toll-like receptor pathways (20) or initiated by in utero 
inflammatory conditions such as histologic chorioamnionitis 
(21). Studies in adults show that trained innate cells, including 
monocytes and natural killer (NK) cells, appear to be epige-
netically and metabolically reprogrammed to produce increased 
amounts of pro-inflammatory cytokines and display higher 
levels of surface activation markers in response to restimulation 
with toll-like receptor ligands or different whole microorgan-
isms (22–25).
If trained immunity is to provide a mechanism of action for 
the non-specific protective effects of BCG, evidence of trained 
immunity in infants or infant innate cells is needed. The immune 
system of the newborn infant differs from that of the adult in 
its constitution as well as in its propensity to respond to dif-
ferent stimuli; differences that reflect the unique physiological 
challenge of transitioning from the intrauterine environment 
to the outside world where some microorganisms are beneficial 
commensals and some are life-threatening pathogens (26, 27). 
Newborn innate immune responses are characterized by a 
reduced capacity for pro-inflammatory cytokines and dendritic 
cell differentiation and activation, but a greater propensity to 
produce regulatory cytokines (28, 29). More data are needed 
on how these differences impact upon the generation of trained 
innate immunity by BCG.
Our aim in this study was to probe the infant immune response 
to mycobacteria-unrelated stimuli following BCG vaccination for 
potential mediators of trained immunity. We used a multiplex 
bead array approach for the detection of secreted cytokines and 
chemokines from diluted whole blood following stimulation with 
a panel of innate stimuli. The rationale for this was to maximize 
the variety of immune cells available for stimulation as well as the 
potential to detect a broad array of soluble mediators. Our data 
provide a description of previously unreported profiles of trained 
immunity in infants and a role for activated NK cells.
MaTerials anD MeThODs
study Participants and sample collection
Healthy, UK-born infants were recruited following ethical approval 
from the National Research Ethics Service Committee London-
East (11/LO/0363) and from the Ethics Committee of the London 
School of Hygiene and Tropical Medicine (ref. 4068). Written 
consent was obtained from parents prior to recruitment. Infants 
were recruited from two regions of South East England: Redbridge, 
where a single dose of intradermal BCG (BCG Vaccine Danish 
Strain 1331, Staten Serum Institute, Copenhagen, Denmark) was 
administered to infants at approximately 6 weeks of age in local 
vaccination clinics and West Essex where infants do not routinely 
receive BCG. Heparinized venous blood was obtained 4 months 
post-vaccination or from unvaccinated infants at an age-matched 
time point. This exploratory study was part of a larger study (11) 
and 4-month post-vaccination samples available were n =  11, 
vaccinated infants; and n = 10, unvaccinated infants for Luminex 
analysis and n = 10 and n = 8, respectively, for flow cytometry 
analysis.
Diluted Whole Blood assays for  
cytokine responses to innate stimuli
Venous blood was diluted 1/5 in RPMI 1640 (Invitrogen) 
 supplemented with 2 mM l-glutamine (Invitrogen) and cultured 
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at 37°C for 48 h in 96-well U-bottomed plates in a final volume 
of 200 µl. Duplicate wells were incubated alone (medium only 
negative control) or with the following stimuli: lipopol ysaccharide 
(LPS; 10 ng/ml); (S)-(2,3-bis(palmitoyloxy)-(2RS) -propyl)-
N-palmitoyl-(R)-Cys-(S)-Ser(S)-Lys4-OH, trihydrochloride 
[Pam3Cys; 10 µg/ml]; heat-killed (HK) Candida albicans (C. 
albicans; 106 microorganisms/ml); HK Staphylococcus aureus (S. 
aureus; 106 microorganisms/ml); HK Escherichia coli (E. coli; 106 
microorganisms/ml); and sonicated Mycobacterium tuberculosis 
H37Rv [Mtb lysate; 1 µg/ml end concentration]. Concentrations 
used for each stimulus were optimized in previous experiments.
Tissue culture supernatant harvest  
and Multiplex Bead array assay
After 48  h, plates were centrifuged at 400  g for 5  min. 
Supernatants were removed from duplicate wells, pooled, and 
stored in aliquots at −80°C prior to analysis. Thawed super-
natants were subjected to multiplex bead array analysis using 
the human cytokine/chemokine Milliplex™ MAP 42-plex pre-
mixed kit (Merck Millipore) and following the manufacturer’s 
instructions. The pre-mixed bead set included the following 
panel: IL-1α, IL-1β, IL-1Ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, 
IL-8, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17, 
epidermal growth factor (EGF), eotaxin, Flt-3L, FGF-2, frac-
talkine, G-CSF, GM-CSF, GRO, IFNα2, IFNγ, IP-10, MCP-1, 
MCP-3, MDC, MIP-1α, MIP-1β, platelet-derived growth fac-
tor (PDGF)-AA, PDGF-AB/BB, RANTES, sCD40L, sIL-2Ra, 
TGFα, TNFα, TNFβ, and VEGF. Data were acquired using the 
Biorad Luminex® 100 system and Bioplex Manager Software 
version 6.1 (Biorad).
Peripheral Blood leukocyte (PBl)  
harvest and Flow cytometry
Following the removal of supernatants from diluted whole blood 
assay plates, remaining PBLs were harvested and cryopreserved 
for later analysis. EDTA in PBS (2 mM) was added to assay wells, 
which were incubated at room temperature for 15 min to detach 
adherent cells. Wells were mixed and cells from duplicate wells 
were pooled and then incubated with 10× volume of 1× FACS 
Lysing Buffer (BD Biosciences) at room temperature for 10 min. 
Following red cell lysis, PBLs were pelleted, resuspended in fetal 
bovine serum with 10% dimethylsulfoxide, and cryopreserved in 
liquid nitrogen. For flow cytometric analysis, thawed cells were 
washed in PBS with 0.1% bovine serum albumin and 0.01% 
sodium azide (both Sigma Aldrich) and stained for 30  min at 
4°C with the following antibodies: CD3-BV510 (clone UCHT1); 
CD25-PerCP-Cy™5.5 (clone M-A251); CD56-PE-Cy™7 (clone 
B159); CD206-PE-CF594 (clone 19.2); HLA-DR-BV605 (clone 
G46-6) (all from BD Biosciences); CD11b-FITC (clone ICRF44); 
CD69-PE (clone FN50); CD163-APC (clone eBioGHI/61) (all 
from Affymetrix/eBiosciences); CD14-BV650 (clone M5E2; 
Biolegend). Following a further wash, cells were resuspended 
in PBS with 1% paraformaldehyde for acquisition. Cells were 
acquired using a BD LSR II flow cytometer (BD Biosciences) 
equipped with blue (488 nm), red (633 nm), and violet (405 nm) 
lasers and FACSDiva 6.1.3 software. Compensation was carried 
out using BD™ CompBead Plus compensation particles stained 
separately with each antibody conjugate and fluorescence minus 
one control stains were used to determine the position of pheno-
type and activation marker analysis gates.
Data analysis, Management, and 
statistical analysis
Multiplex bead array data for each stimulation condition were 
background subtracted using values measured in unstimulated 
controls. Background levels of each cytokine/chemokine are 
given in Table S1 in Supplementary Material. Final concentra-
tions below the lower limit of quantitation were adjusted to 
the value of the lowest standard (3.2 pg/ml) and data above the 
upper limit of quantitation were adjusted to the highest standard 
(10,000  pg/ml). The compensation matrix was generated and 
flow cytometric data were analyzed using FlowJo™ 10.2 soft-
ware (FlowJo LLC). Monocytes were gated based on CD14 and 
HLA-DR expression as well as on size and granularity. NK cells 
were gated based on CD56 expression and lack of CD3 expres-
sion (see Figure S1 in Supplementary Material). Multiplex bead 
array data were analyzed using IBM® SPSS® Statistics version 
23 software (IBM Corp.) and Prism 7 for Windows (GraphPad 
Software Inc.). Flow cytometric data were further analyzed using 
a combination of Spice 5.35 (30) and Prism. Statistical com-
parisons between vaccinated and unvaccinated infant groups 
for both multiplex bead array and flow cytometry data were by 
Mann–Whitney U test and correlations were by Spearman’s rank 
correlation coefficient.
resUlTs
infant Bcg Vaccination is associated  
with enhanced cytokine and chemokine 
responses to non-specific innate stimuli
Diluted whole blood from BCG-vaccinated and unvaccinated 
infants was stimulated with a panel of non-specific innate stimuli 
and with a preparation of Mtb lysate. Secreted cytokines and 
chemokines were measured in tissue culture supernatants by 
multiplex bead array after 48 h.
Previous reports described TNFα, IL-6, and IL-1β as the 
characteristic cytokines of BCG-induced trained innate immu-
nity in adults (24, 31). However, when we investigated this 
signature in infants, only IL-6 was significantly increased in 
response to non-specific stimuli. Re-stimulation with the myco-
bacterial stimulant Mtb lystae did produce a significant increase 
in TNFα (Figure 1). As expected, Mtb lystae induced the most 
extensive upregulation of responses in BCG-vaccinated infants 
including 27 cytokines and chemokines that characterize 
both innate and adaptive T-cell responses (Figures  1 and 2; 
Table 1). We detected 11 cytokines and chemokines that were 
significantly increased and 6 that were significantly decreased in 
BCG-vaccinated infants in response to non-specific stimulants 
(Figure  2; Table  1). Each non-specific stimulant induced a 
distinct response profile. For example, increases in 10 cytokines 
and chemokines were detected following Pam3Cys stimulation 
FigUre 1 | Cytokine profile of bacillus Calmette–Guérin (BCG)-induced trained immunity in infants does not include TNFα or IL-1β. TNFα, IL-6, and IL-1β 
concentrations were measured in tissue culture supernatants after diluted whole blood from BCG-vaccinated (□, n = 11) and unvaccinated (○, n = 10) infants 
was cultured for 48 h with the indicated stimulants. Data shown is background subtracted (unstimulated samples). Wide bars indicate median response; narrow 
bars indicate 25th and 75th percentiles. Responses in vaccinated and unvaccinated groups were compared using the Mann–Whitney U test: **p < 0.01; 
*p < 0.05.
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whereas C. albicans stimulation revealed BCG-associated 
increases in four analytes: EGF, IL-6, PDGF-AB/BB, MCP-3, 
but decreases in four further analytes: IL-2, IL-13, IL-17, IP-10. 
Despite distinct response profiles for each non-specific stimu-
lant, we observed a common signature of increases in EGF, IL-6, 
and PDGF-AB/BB in response to three different stimulants: 
Pam3Cys, C. albicans, and S. aureus.
These data led us to conclude that BCG vaccination of infants, 
in this setting, induces a complex reprogramming of the innate 
immune system to respond mainly in an enhanced fashion when 
exposed in vitro to a panel of heterogeneous, non-specific stimuli. 
For a few cytokines, downregulation of production was observed 
after vaccination. Overall, this effect is consistent with trained 
immunity which is known to be mediated by cells of the innate 
immune system.
nK cell cD69 expression is increased  
in Bcg-Vaccinated infants following  
Pam3cys re-stimulation In Vitro
To determine which innate immune cells were associated with 
altered cytokine and chemokine responses to non-specific stimuli 
in BCG-vaccinated infants, we stained PBLs recovered from 48 h 
diluted whole blood assays for markers of monocyte and NK cell 
phenotype and activation.
Consistent with BCG-associated increases in a broad array 
of cytokine and chemokine responses following Mtb lystae res-
timulation, we also detected concomitant increases in expression 
of CD11b and CD206 on monocytes (Figure  3A). There were 
no significant, BCG vaccination-associated changes to monocyte 
activation markers in response to non-specific stimuli. In addition 
FigUre 2 | Continued
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to its effect on monocytes, Mtb lystae stimulation also induced 
increased surface expression of the activation marker CD69 on 
NK cells (Figure 3B). Although there were no significant changes 
to monocyte activation markers in response to non-specific 
stimuli, BCG-vaccinated infants displayed a significant increase 
in NK cell CD69 expression in response to Pam3Cys (Figure 3B).
Based on these data, we conclude that, accompanying the 
cytokine/chemokine profile of BCG-induced trained immunity 
in infants, there is a role for activated NK  cells but that their 
involvement depends upon the nature of the restimulating non-
specific ligand.
Pam3cys-induced nK cell activation 
correlates with the secretion of  
il-12p40 and il-10
Pam3Cys is a ligand for TLR2 which is found on the surface of 
NK cells. We speculated that enhanced Pam3Cys-induced NK cell 
activation in BCG-vaccinated infants could be a result of changes 
to the cytokine milieu that this ligand induces (Figure 2) or due to 
intrinsic changes to NK cells following BCG vaccination that alter 
their responsiveness to TLR2-mediated Pam3Cys stimulation or 
a combination of the two. Although the scope of this study did 
TaBle 1 | BCG vaccination-associated cytokine and chemokine responses induced by specific and non-specific stimuli in 48 h diluted whole blood assays.
stimulation Overexpressed in Bcg-vaccinated infants Median fold 
change
Under-expressed in Bcg-
vaccinated infants
Median fold 
change
Mtb lysate IL-2, IFNγ, IL-13, IL-1α, IP-10, IL-6 >10
Flt-3L, IL-8, IL-1Rα, IL-12p40, IL-10, MCP-3 5–10
MIP-1α, IL-5, TNFα, VEGF, MIP-1β, GM-CSF, IL-7, IL-17, IFNα2, eotaxin 2–5
CD40L, TNFβ, fractalkine, FGF- 2, TGFα 1–2
Pam3Cys IL-10, epidermal growth factor (EGF) 5–10
Platelet-derived growth factor (PDGF)-AB/BB, sCD40L, MIP-1α 2–5
IL-12p40, IL-6, MCP-3, IL-7, eotaxin 1–2
Candida albicans EGF, IL-6, PDGF-AB/BB, MCP-3 2–5 IL-2, IL-13, IL-17, IP-10 0.2–0.5
Staphylococcus aureus EGF, IL-6 2–5
PDGF-AB/BB 1.7
Escherichia coli EGF 2.8 GM-CSF, GRO 0.2–1.0
Lipopolysaccharide IL-8 1.7 GM-CSF, GRO 0.2–1.0
FigUre 2 | Distinct patterns of cytokine and chemokine secretion characterize bacillus Calmette–Guérin (BCG)-induced trained immunity in response to different, 
non-specific stimuli. The concentrations of 42 cytokines and chemokines were measured in 48 h, diluted whole blood assay supernatants using multiplex bead array. 
(a) Heat maps represent the vaccination effect [the log2 median fold change in analyte concentration in the BCG-vaccinated infants (n = 11) compared to unvaccinated 
infants (n = 10)] on the indicated cytokine/chemokine responses to different stimuli: ML, Mtb lysate; LPS, lipopolysaccharide; EC, E. coli; P3C, Pam3Cys; CA, C. 
albicans; SA, S. aureus. (B) Volcano plots represent the vaccination effect on cytokine/chemokine responses to different indicated stimuli which are plotted on the x-axis 
against the −log10 p value on the y-axis (calculated by Mann–Whitney U test comparisons of responses in BCG-vaccinated and unvaccinated groups). Data points 
represent individual cytokines and chemokines. Significant responses of interest are labeled where clarity permits. Horizontal dotted lines represent a p value of 0.05.
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not allow us to address the intrinsic changes hypothesis, we were 
able to look at associations between the magnitude of Pam3Cys-
mediated NK  cell activation and the changes in cytokine and 
chemokine release in response to the same stimulant. Of the 10 
analytes that were significantly upregulated in BCG-vaccinated 
infants in response to Pam3Cys, IL-12p40 and IL-10 secretion 
FigUre 3 | Bacillus Calmette–Guérin (BCG) vaccination of infants is associated with enhanced natural killer (NK) cell activation in response to Pam3Cys. Following 
48 h, diluted whole blood assay stimulation of samples from BCG-vaccinated (□, n = 10) and unvaccinated (○, n = 8) infants, cell pellets were cryopreserved and 
later analyzed by flow cytometry. (a) Monocytes were identified based on high CD14 and HLA-DR expression as well as on size and granularity (see Figure S1A in 
Supplementary Material) and stained for the indicated markers of monocyte activation and differentiation. Data points represent the fold change in MFI for samples 
incubated with the indicated stimulants compared to unstimulated samples. (B) CD56+ CD3− NK cells were gated (see Figure S1B in Supplementary Material) and 
the expression of the activation markers CD69 and CD25 analyzed. Data points represent the fold change in percent of activation marker expressing NK cells for 
samples incubated with the indicated stimulants compared to unstimulated samples. Responses in vaccinated and unvaccinated groups were compared using the 
Mann–Whitney U test: *p < 0.05; **p < 0.01.
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demonstrated significant correlation with the extent of NK cell 
CD69 expression (Figure 4).
From these data, we conclude that cytokine secretion, most 
notably IL-12, may account at least in part for the TLR2-mediated 
activation of NK cells in BCG-vaccinated infants.
DiscUssiOn
Trained innate immunity has, to date, been demonstrated and 
characterized largely in adults. Isolated PBMC released more TNFα, 
IL-6, and IL-1β when exposed to non-specific innate stimuli 
3  months after BCG vaccination in adults, and monocytes dis-
played higher levels of activation markers (24). Mechanisms of 
trained immunity such as underlying epigenetic regulation and 
shifts in the metabolic pathways used have similarly been revealed 
in vaccinated adults and in adult cellular models in vitro (22, 32). If 
trained innate immunity is to provide a causal link between BCG 
vaccination of infants and non-specific protection against mortal-
ity due to infectious diseases other than those with a mycobacterial 
etiology (15, 16), then a detailed description of the phenomenon 
in infants and infant cells is needed.
In this paper, we have profiled the infant whole blood cytokine 
and chemokine secretome of trained immunity following BCG 
vaccination using a panel of non-specific innate stimuli and reveal 
a differentially expressed signature. A total of 11 analytes were 
overexpressed and 6 under-expressed in vaccinated infants, 
with different innate stimuli inducing distinct combinations of 
response elements: for example, the Pam3Cys-induced response 
included the overexpression of 10 analytes, while S. aureus only 
induced three analytes. Four analytes were overexpressed and 
four under-expressed in response to C. albicans; LPS and E. 
coli each induced one overexpressed and two under-expressed 
analytes. These distinctions most likely reflect the different 
characteristics of the stimuli involved. Two of them, LPS and 
Pam3Cys, are defined biochemical compounds that interact with 
specific pattern recognition receptors: TLR4 and TLR2/1 heter-
odimer, respectively. C. albicans, S. aureus, and E. coli are all HK 
preparations of microorganisms containing complex mixtures of 
pathogen-associated molecular patterns that will interact with an 
array of different pathogen recognition receptors or other innate 
antigen receptors. It has been suggested that different microorgan-
isms act on multiple, distinct TLRs simultaneously in a manner 
likened to the playing of a unique “chord” on a “molecular piano” 
(17) and the different response profiles generated by different 
stimuli described here may be an illustration of that effect.
The pathways by which BCG mediates its training effect in vivo 
are yet to be fully elucidated, although a role for the mycobacterial 
cell wall component muramyl dipeptide, acting via the NOD2 
receptor, has been described (24). β-glucan, another activator 
of trained immunity mediates its effects via a dectin-1/Raf1-
dependant pathway (33), yet the role of dectin-1 in recognizing 
mycobacteria is probably minor at most. The emerging picture 
is one in which the recall of a trained immune response may be 
restimulated via different receptors to those that prime that same 
FigUre 4 | Correlation between Pam3Cys (P3C)-induced natural killer  
(NK) cell CD69 expression and IL-12p40 and IL-10 secretion. P3C-specific, 
NK cell CD69 expression in samples from bacillus Calmette–Guérin 
(BCG)-vaccinated (□, n = 10) and unvaccinated (○, n = 8) infants were 
plotted against P3C-specific secretion of IL-12p40 and IL-10 in the same 
samples. The degree of correlation was measured using Spearman’s rank 
correlation coefficient.
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response and that the cytokine/chemokine signature of that recall 
is determined by the receptors involved. Although little is known 
at this time about the mechanisms responsible, this should be a 
focus of future studies.
Despite the differences described above, we described here 
a biosignature of BCG-induced trained innate immunity in 
infants comprising increases in EGF, IL-6, and PDGF-AB/BB, 
all of which were apparent in responses to three different innate 
stimuli. This is different to the characteristic signature of trained 
innate immunity in adults, which includes TNFα and IL-1β as 
well as IL-6. It must be however underlined that in adults not all 
the cytokines reported here were measured, and some of them 
may be upregulated as well in older individuals. The absence of 
canonical innate cytokines such as TNFα in this infant biosig-
nature may reflect the maturation of the infant innate immune 
response, whereby the ability to make certain cytokines develop 
over the first 9 months of life (34). Despite the most extensive 
response profile, Mtb lystae stimulation did not upregulate EGF 
or PDGF-AB/BB. This may reflect the involvement of a broader 
array of pattern recognition receptors in response to Mtb lystae 
with downstream effects that manifest themselves as a distinct 
pattern of upregulated and downregulated markers. These 
observations illustrate the importance of an unbiased, multiplex 
approach to analyzing these responses. A more directed study 
focused on TNFα, IL-6, and IL-1β would have underestimated 
the effect of trained immunity in infants and would have missed 
the previously unreported markers EGF and PDGF-AB/BB, as 
well as the finding that C. albicans-induced trained immunity 
recall in BCG-vaccinated infants involves reduced IL-2, IL-13, 
IL-17, and IP-10 responses. It is interesting that IL-17 responses 
to C. albicans are reduced in vaccinated infants. Th-17 cells 
are known to be important in immune responses to C. albicans 
(35). BCG vaccination has been shown to enhance non-specific 
(innate-mediated) protection against candidiasis in SCID mice 
(24) and adult BCG vaccination activates heterologous Th-17 
responses specific for non-mycobacterial ligands including C. 
albicans (31). Our data suggest that BCG is exerting a different 
influence on the infant immune response, steering it away from a 
bias toward Th-17 development that is known to exist in early life 
(36). Detailed analyses of epigenetic and transcriptional programs 
of training or tolerance induction have revealed upregulation 
and downregulation of genes that characterize these responses 
hence it is unsurprising that the profiles we report here involve 
both upregulation and downregulation of different cytokines 
and chemokines associated with both T-cell and inflammatory 
monocyte responses to stimuli such as C. albicans as well as to E. 
coli and LPS which have both been associated with the induction 
of tolerance (37, 38).
In contrast to our findings here, another report of infant BCG-
associated, non-specific cytokine responses described increases 
in TNFα and IL-1β as well as in IL-6 in response to Pam3Cys 
(39). Differences between study designs that might explain this 
difference are that Jensen et al. carried out their study in a low-
income country and in low birth weight infants. In addition, the 
genetic backgrounds of the populations studied were different. 
Their sampling time point of 4 weeks was earlier than that used 
here and there were some methodological differences in their 
whole blood assay. An interesting possible explanation is that, 
unlike Jensen et al., infants in our study had received DTP vac-
cination through the national vaccination program by the time of 
sampling which is thought to negatively affect the positive non-
specific effects of BCG (40). Finally, compared to Jensen et al., 
our study was relatively small and exploratory and was possibly 
underpowered to detect small differences in cytokine responses. 
It should be noted that in agreement with our findings and those 
of others (7), Jensen et al. found no BCG-associated increase in 
TNFα in response to non-specific LPS stimulation.
The involvement of monocytes in adult trained immunity has 
been demonstrated using stimulating ligands that interact with 
receptors known to be found on monocytes and more directly 
by the demonstration that markers of monocyte activation and 
differentiation are upregulated following training (24). It is 
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also possible to isolate adult blood monocytes and train them 
directly with BCG and β-glucan in  vitro (32). Although the 
assay described in this paper was designed primarily to look at 
secreted cytokines and chemokines, it was possible to harvest 
PBLs and to examine monocytes and NK  cells for evidence 
of BCG vaccination-associated trained innate activation. We 
examined four markers of monocyte activation, but found no 
significant differences in their expression following non-specific 
stimulation of samples from vaccinated and unvaccinated infants. 
Stimulation with Mtb lystae, which also induced increases in 27 
cytokines and chemokines in vaccinated infants, did increase 
levels of CD11b and CD207 on the surface of monocytes. Unlike 
responses induced by non-specific ligands in these experiments, 
it is likely that antigen-specific T-cell help is involved in these 
changes in monocyte activation. It is interesting that monocytes 
from BCG-vaccinated infants show increased expression of 
CD207 (mannose receptor), as this is usually found only on 
certain populations of differentiated macrophages and dendritic 
cells (41).
Natural killer cells from BCG-vaccinated infants displayed 
increased levels of the activation marker CD69 in response to 
Pam3Cys, as well as to Mtb lystae. Previous work has described 
long-lived mycobacteria-specific NK cells following infant BCG 
as well as a role for NK cells in BCG-induced trained immunity in 
adults and in BCG-vaccinated SCID mice which show increased 
resistance to C. albicans infection (25, 42). However, this is the 
first time their involvement in trained immunity to heterologous 
stimuli in infants has been described. NK cells express the TLR2 
receptor via which they are reported to interact with mycobacteria 
(43, 44). NK cells are also activated in response to type 1 cytokines 
(45). Although we cannot determine the pathway of NK  cell 
activation from the current data, we did observe a correlation 
between CD69 expression, IL-12p40 secretion, and IL-10 secre-
tion in response to Pam3Cys. IL-12 is known to be a soluble 
activator of NK  cells, while a role for IL-10 is less obvious. A 
limitation of this study was the small volume of blood available 
from infants which meant it was not possible to identify the cell 
type producing the cytokines and chemokines described. Clearly 
it would be interesting to determine whether the NK responses 
described above or other populations were a source, either by 
depletion studies or intracellular cytokine staining and future 
studies should address this. Additionally, as well as stimulation 
of the TLR2/1 heterodimer using Pam3Cys, it would be useful 
in future to determine more precisely the role of TLR2 either in 
homodimeric form or as a heterodimer with TLR6 also using 
specific ligands for these receptors.
This exploratory study was not designed to investigate the het-
erologous effects of infant BCG vaccination on clinical outcomes; 
however, if the non-specific immune responses we describe are to 
provide a mechanism for these effects, a causal relationship will 
need to be demonstrated in a larger study. The setting of such a 
study will need to be carefully considered as to date, the results 
of clinical trials have been mixed. Heterologous, BCG-induced 
protection against clinical outcomes related to infectious disease 
has been observed in a low-income setting in West Africa (15, 46) 
but was not recapitulated in another trial in a high income, 
European setting (47, 48).
In conclusion, we have described a novel whole blood signa-
ture of BCG-induced, trained innate immunity in infants that 
includes secretion of EGF, IL-6, and PDGF-AB/BB and involves 
activated NK cells. We also show distinct patterns of cytokine and 
chemokine release in response to different innate ligands. The 
data show different patterns to previously published descriptions 
of BCG-induced trained innate immunity in adults and low birth 
weight infants and suggest that more, larger scale studies of this 
effect in different populations are required for a more complete 
understanding.
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